SCHEMBL19377264

SCHEMBL19377264

CC(NC(=O)Nc1ccc(S(=O)(=O)Cc2ccc3c(c2)CCN3)cc1)c1cccc(Cl)c1Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MLNR O43193 4/20 0.39
▸ HDAC3 O15379 1/20 0.36
▸ HDAC4 P56524 1/20 0.36
▸ HDAC1 Q13547 1/20 0.36
▸ HDAC7 Q8WUI4 1/20 0.36
▸ HDAC2 Q92769 1/20 0.36
▸ HDAC10 Q969S8 1/20 0.36
▸ HDAC11 Q96DB2 1/20 0.36
▸ HDAC8 Q9BY41 1/20 0.36
▸ HDAC6 Q9UBN7 1/20 0.36
▸ HDAC9 Q9UKV0 1/20 0.36
▸ HDAC5 Q9UQL6 1/20 0.36
▸ CCR3 P51677 1/20 0.35
▸ GHSR Q92847 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ NAMPT P43490 4/20 0.34
▸ GRM4 Q14833 2/20 0.34
▸ PCTP Q9UKL6 1/20 0.34
▸ STARD10 Q9Y365 1/20 0.34
▸ IDH1 O75874 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19377263 1.00 MLNR (0.39) MLNRHDAC3HDAC4HDAC1HDAC7
SCHEMBL19377189 0.93 MLNR (0.39) MLNRHDAC3HDAC4HDAC1HDAC7
SCHEMBL19377188 0.93 MLNR (0.39) MLNRHDAC3HDAC4HDAC1HDAC7
SCHEMBL19377656 0.88 MLNR (0.46) MLNR
SCHEMBL19377658 0.88 MLNR (0.46) MLNR
SCHEMBL19377366 0.88 MLNR (0.46) MLNR
SCHEMBL19377369 0.88 MLNR (0.46) MLNR
SCHEMBL19398854 0.86 NPC1 (0.42) MLNRLMNAMAPT
SCHEMBL19377071 0.86 MLNR (0.39) MLNRCCR3GHSRLMNAPCTP
SCHEMBL19377070 0.86 MLNR (0.39) MLNRCCR3GHSRLMNAPCTP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3390355-B1 BENZENESULFONYL-ASYMMETRIC UREAS AND MEDICAL USES THEREOF HELSINN HEALTHCARE SA (CH) 2022-12-28 — — EP claimed
US-20170275301-A1 Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof HELSINN HEALTHCARE SA (CH) 2017-09-28 — — US claimed
EP-3390355-B1 BENZENESULFONYL-ASYMMETRIC UREAS AND MEDICAL USES THEREOF HELSINN HEALTHCARE SA (CH) 2022-12-28 — — EP disclosed
EP-3390355-B1 BENZENESULFONYL-ASYMMETRIC UREAS AND MEDICAL USES THEREOF HELSINN HEALTHCARE SA (CH) 2022-12-28 — — EP disclosed
US-20170275301-A1 Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof HELSINN HEALTHCARE SA (CH) 2017-09-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170275301-A1 Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof UTS2R, GHSR, GRPR MLNR 24/4885HDAC3 1409/4885HDAC4 1324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback